Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

v3.24.3
Intangible Assets
 9 Months Ended
Sep. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
Intangible assets as of September 28, 2024 and December 30, 2023 consist of the following (in $000’s):
September 28,
2024		 December 30,
2023
Soin intangibles * $ 19,293  $ 19,293 
Customer relationships 13,925  — 
Trade names 2,675  — 
Developed technology 1,850  — 
Patents and domains $ 4  $ 4 
Intangible assets 37,747  19,297 
Less accumulated amortization (3,770) (1,451)
Total intangible assets $ 33,977  $ 17,846 
*The Soin intangibles acquired by the Company consist of the following:
1.Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain;
2.Final formula for Naltrexone; and
3.Orphan drug designation as approved by the FDA.
Intangible amortization expense was $2.1 million and $363,000 for the 13 weeks ended September 28, 2024 and September 30, 2023 and $2.3 million and $1.1 million for the 39 weeks ended September 28, 2024 and September 30, 2023.